Analytical Data
-
Gene name
GAD2
- Application
-
Alternative Names
GAD65; Glutamate Decarboxylase 2, Acid; Pancreatic Islets And Brain,65kDa; 65 kDa glutamic acid decarboxylase; Glutamate decarboxylase 65 kDa isoform
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q05329
-
Expression Region
Met188~Ser374
-
Molecular Weight
20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GAD2 (Glutamate Decarboxylase 2) is an important enzyme responsible for the synthesis of gamma-aminobutyric acid (GABA), a crucial neurotransmitter that plays a significant role in inhibitory signaling within the central nervous system. Research on GAD2 is pivotal due to its involvement in various neurological conditions, including epilepsy, anxiety disorders, and schizophrenia. The recombinant expression of GAD2 protein allows for in-depth studies of its enzymatic properties, regulatory mechanisms, and interactions with other biomolecules. Additionally, understanding the structure-function relationship of GAD2 through recombinant techniques can facilitate the development of therapeutic strategies aimed at modulating GABAergic signaling. As the prevalence of mood and anxiety disorders continues to rise, exploring GAD2-encoded pathways has the potential to yield novel biomarkers and drug targets for clinical intervention. Overall, the study of GAD2 recombinant protein serves as a critical step toward elucidating the complexities of neurotransmitter regulation and offers promise for advancing neurological health.
